GlassScriptPhysician profile
Dianne R Harrison
NPI 1033752803
$425.84
in general payments reported to CMS, 2019-2025
10 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.76 · 2022: $123 · 2023: $14.20 · 2024: $124 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.94 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $75.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.26 | 2021-2024 | Farxiga |
| Supernus Pharmaceuticals, INC. | $36.17 | 2024 | Qelbree |
| Xeris Pharmaceuticals, INC. | $30.99 | 2024-2025 | Gvoke Hypopen |
| Abbvie INC. | $29.91 | 2025 | |
| Novo Nordisk INC | $28.30 | 2023-2024 | Rybelsus, Ozempic |
| Vertex Pharmaceuticals Incorporated | $15.78 | 2025 | |
| Lilly USA, LLC | $15.56 | 2024 | Zepbound, Mounjaro |
| Pfizer INC. | $13.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.